期刊
BRITISH JOURNAL OF CANCER
卷 110, 期 4, 页码 984-990出版社
NATURE PUBLISHING GROUP
DOI: 10.1038/bjc.2013.815
关键词
malignant pleural mesothelioma; fibrinogen; prognosis; predictive biomarker; multimodality therapy
类别
资金
- 'Initiative Krebsforschung' of the Medical University Vienna
- OTKA [K 108465, K109626]
- TAMOP [424A/1-11-1-2012-0001]
- KTIA [AIK 12-1-2013-0041]
Background: To investigate the clinical utility of pretreatment plasma fibrinogen levels in malignant pleural mesothelioma (MPM) patients. Methods: A retrospective multicenter study was performed in histologically proven MPM patients. All fibrinogen levels were measured at the time of diagnosis and clinical data were retrospectively collected after approval of the corresponding ethics committees. Results: In total, 176 MPM patients (mean age: 63.5 years +/- 10.4 years, 38 females and 138 males) were analysed. Most patients (n = 154, 87.5%) had elevated (>= 390 mg dl(-1)) plasma fibrinogen levels. When patients were grouped by median fibrinogen, patients with low level (<= 627 mg dl(-1)) had significantly longer overall survival (OS) (19.1 months, confidence interval (CI) 14.5-23.7 months) when compared with those with high level (OS 8.5; CI 6.2-10.7 months). In multivariate survival analyses, fibrinogen was found to be an independent prognostic factor (hazard ratio 1.81, CI 1.23-2.65). Most interestingly, fibrinogen (cutoff 75th percentile per 750 mg dl(-1)) proved to be a predictive biomarker indicating treatment benefit achieved by surgery within multimodality therapy (interaction term: P = 0.034). Accordingly, only patients below the 75th percentile benefit from surgery within multimodality therapy (31.3 vs 5.3 months OS). Conclusions: Fibrinogen is a novel independent prognostic biomarker in MPM. Most importantly, fibrinogen predicted treatment benefit achieved by surgery within multimodality therapy.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据